ArticleThe Journal of clinical investigation2000
Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone.
Article in The Journal of clinical investigation, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 158 citations in OpenAlex.
- Trial
- An in silico approach to elucidate the pathways leading to primary osteoporosis: age-related vs. postmenopausal.Biomechanics and modeling in mechanobiology · 2024Article
- Review
- Osteoclast-derived IGF1 induces RANKL production in osteocytes and contributes to pagetic lesion formation.JCI insight · 2023Article
- Paget's Disease of the Bone and Lynch Syndrome: An Exceptional Finding.Diagnostics (Basel, Switzerland) · 2023Article
- Updates on Paget's Disease of Bone.Endocrinology and metabolism (Seoul, Korea) · 2022Article
- miR profile in pagetic osteoclasts: from large-scale sequencing to gene expression study.Journal of molecular medicine (Berlin, Germany) · 2021Article
- Article
- Global deletion of Optineurin results in altered type I IFN signaling and abnormal bone remodeling in a model of Paget's disease.Cell death and differentiation · 2020Article
- Article
- Zoledronic acid prevents pagetic-like lesions and accelerated bone loss in the p62Disease models & mechanisms · 2018Article
- Interleukin-6 Interweaves the Bone Marrow Microenvironment, Bone Loss, and Multiple Myeloma.Frontiers in endocrinology · 2018Review
- Key Triggers of Osteoclast-Related Diseases and Available Strategies for Targeted Therapies: A Review.Frontiers in medicine · 2017Review
- Beyond Antibodies: B Cells and the OPG/RANK-RANKL Pathway in Health, Non-HIV Disease and HIV-Induced Bone Loss.Frontiers in immunology · 2017Review
- Measles virus nucleocapsid protein increases osteoblast differentiation in Paget's disease.The Journal of clinical investigation · 2016Article
- Aberrant Activation of the RANK Signaling Receptor Induces Murine Salivary Gland Tumors.PloS one · 2015Article
- Genetics of Paget's disease of bone.Current osteoporosis reports · 2014Review
- A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.Artificial organs · 2014Article
- Pathobiology of Paget's Disease of Bone.Journal of bone metabolism · 2014Review
- Genotype-phenotype correlation in juvenile Paget disease: role of molecular alterations of the TNFRSF11B gene.Endocrine · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
Abstract
Paget's disease is characterized by highly localized areas of increased osteoclast (OCL) activity. This suggests that the microenvironment in pagetic lesions is highly osteoclastogenic, or that OCL precursors in these lesions are hyperresponsive to osteoclastogenic factors (or both). To examine these possibilities, we compared RANK ligand (RANKL) mRNA expression in a marrow stromal cell line developed from a pagetic lesion (PSV10) with that in a normal stromal cell line (Saka), and expression in marrow samples from affected bones of Paget's patients with that in normal marrow. RANKL mRNA was increased in PSV10 cells and pagetic marrow compared with Saka cells and normal marrow, and was also increased in marrow from affected bones compared with uninvolved bones from Paget's patients. Furthermore, pagetic marrow cells formed OCLs at much lower RANKL concentrations than did normal marrow. Anti-IL-6 decreased the RANKL responsivity of pagetic marrow to normal levels, whereas addition of IL-6 to normal marrow enhanced RANKL responsivity. Thus, RANKL expression and responsivity is increased in pagetic lesions, in part mediated by IL-6. These data suggest that the combination of enhanced expression of RANKL in affected bones and increased RANKL sensitivity of pagetic OCL precursors may contribute to the elevated numbers of OCLs in Paget's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.